18:00-19:30
|
Session 1: Controversies in neoadjuvant chemotherapy Hall A
|
| Chairpersons |
Javier Cortes, Spain
Richard De Boer, Australia
|
| 18:00-18:30 |
Debate: That neoadjuvant systemic therapy should be standard of care for all operable breast cancer >2cm
Yes: Stephen R.D. Johnston, UK
No: Edith A. Perez, USA
Discussion |
|
| 18:30-19:00 |
Debate: That pathological confirmation of the axillary status is required before neoadjuvant systemic therapy
Yes: Alastair Thompson, USA
No: Andrew Spillane, Australia
Discussion |
|
| 19:00-19:30 |
Debate: That pathological CR is an appropriate and accurate surrogate endpoint for long term breast cancer outcomes
Yes: Laura Esserman, USA
No: Elgene Lim, Australia
Discussion |
|
| 19:30-20:30 |
Networking Reception
|
